SG11202001449VA - Process for lyophilized pharmaceutical formulation of a therapeutic protein - Google Patents

Process for lyophilized pharmaceutical formulation of a therapeutic protein

Info

Publication number
SG11202001449VA
SG11202001449VA SG11202001449VA SG11202001449VA SG11202001449VA SG 11202001449V A SG11202001449V A SG 11202001449VA SG 11202001449V A SG11202001449V A SG 11202001449VA SG 11202001449V A SG11202001449V A SG 11202001449VA SG 11202001449V A SG11202001449V A SG 11202001449VA
Authority
SG
Singapore
Prior art keywords
pharmaceutical formulation
therapeutic protein
lyophilized pharmaceutical
lyophilized
therapeutic
Prior art date
Application number
SG11202001449VA
Other languages
English (en)
Inventor
Clea Talley
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63686145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202001449V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202001449VA publication Critical patent/SG11202001449VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11202001449VA 2017-09-15 2018-09-10 Process for lyophilized pharmaceutical formulation of a therapeutic protein SG11202001449VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762559420P 2017-09-15 2017-09-15
PCT/US2018/050305 WO2019055357A1 (fr) 2017-09-15 2018-09-10 Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique

Publications (1)

Publication Number Publication Date
SG11202001449VA true SG11202001449VA (en) 2020-03-30

Family

ID=63686145

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001449VA SG11202001449VA (en) 2017-09-15 2018-09-10 Process for lyophilized pharmaceutical formulation of a therapeutic protein

Country Status (22)

Country Link
US (2) US20190083402A1 (fr)
EP (1) EP3681483B1 (fr)
JP (2) JP2020534255A (fr)
KR (1) KR20200054251A (fr)
CN (1) CN111148510A (fr)
AU (1) AU2018334502A1 (fr)
BR (1) BR112020004902A2 (fr)
CA (1) CA3072600A1 (fr)
CL (1) CL2020000625A1 (fr)
DK (1) DK3681483T3 (fr)
EA (1) EA202090731A1 (fr)
ES (1) ES2925232T3 (fr)
HU (1) HUE059339T2 (fr)
IL (2) IL297824A (fr)
LT (1) LT3681483T (fr)
MA (1) MA50239A (fr)
MX (1) MX2020002896A (fr)
PL (1) PL3681483T3 (fr)
PT (1) PT3681483T (fr)
SG (1) SG11202001449VA (fr)
SI (1) SI3681483T1 (fr)
WO (1) WO2019055357A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111595658B (zh) * 2020-06-06 2023-11-14 宾傲 一种提取细胞中蛋白的裂解液及其制备方法
WO2022006336A1 (fr) * 2020-07-01 2022-01-06 Jubilant Pharma Holdings Inc. FORME PHARMACEUTIQUE INJECTABLE À ACTION PROLONGÉE D'AGONISTES DES RÉCEPTEURS β3-ADRÉNERGIQUES
CN114681592A (zh) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 包含可溶性gp130二聚体的制剂和使用方法
CN113087782B (zh) * 2021-04-09 2021-12-14 北京美联泰科生物技术有限公司 一种中枢神经特异性蛋白的冻干方法
TW202313108A (zh) * 2021-06-01 2023-04-01 美商安進公司 製備凍乾蛋白配製物之加速方法
AU2023241233A1 (en) * 2022-03-24 2024-08-15 Richter Gedeon Nyrt. Method for the manufacture of biopharmaceuticals
CN115932239B (zh) * 2022-12-22 2024-02-20 广州市进德生物科技有限公司 一种氧化低密度脂蛋白保护剂、测定氧化低密度脂蛋白的检测试剂盒及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
CA2466641A1 (fr) 2001-11-09 2003-05-22 Centocor, Inc. Compositions lyophilisees d'anticorps monoclonaux
WO2004039337A2 (fr) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Formulations pharmaceutiques liquides stables d'anticorps ayant tendance a l'isomerisation
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
WO2007074880A1 (fr) * 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha Préparation stabilisatrice contenant des anticorps
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2144624A1 (fr) 2007-05-15 2010-01-20 Stryker Corporation Préparations de protéines concentrées de protéines morphogénétiques d'os et procédés d'utilisation correspondant
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
WO2012066058A1 (fr) 2010-11-16 2012-05-24 Boehringer Ingelheim International Gmbh Agents et méthodes de traitement de maladies qui sont corrélées à une expression de bcma
WO2013096791A1 (fr) 2011-12-23 2013-06-27 Genentech, Inc. Procédé pour fabriquer des formulations de protéine à concentration élevée
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
WO2014179648A2 (fr) * 2013-05-02 2014-11-06 The University Of North Carolina At Chapel Hill Addition anti-markovnikov directe d'acides sur des alcènes
US10918698B2 (en) * 2014-03-29 2021-02-16 Intas Pharmaceuticals Ltd. Lyophilized pharmaceutical composition of Fc-peptide fusion protein
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص

Also Published As

Publication number Publication date
EP3681483A1 (fr) 2020-07-22
EA202090731A1 (ru) 2020-06-11
LT3681483T (lt) 2022-09-12
BR112020004902A2 (pt) 2020-09-15
JP2020534255A (ja) 2020-11-26
CA3072600A1 (fr) 2019-03-21
IL272513A (en) 2020-03-31
ES2925232T3 (es) 2022-10-14
PT3681483T (pt) 2022-08-22
SI3681483T1 (sl) 2022-10-28
MX2020002896A (es) 2020-07-22
PL3681483T3 (pl) 2022-09-26
CL2020000625A1 (es) 2020-08-21
MA50239A (fr) 2020-07-22
KR20200054251A (ko) 2020-05-19
AU2018334502A1 (en) 2020-03-12
JP2023126930A (ja) 2023-09-12
CN111148510A (zh) 2020-05-12
US20210369616A1 (en) 2021-12-02
WO2019055357A1 (fr) 2019-03-21
HUE059339T2 (hu) 2022-11-28
IL272513B2 (en) 2023-04-01
IL272513B (en) 2022-12-01
IL297824A (en) 2023-01-01
DK3681483T3 (da) 2022-08-29
EP3681483B1 (fr) 2022-05-18
US20190083402A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
IL272513A (en) Lyophilization process for pharmaceutical formulation of medical protein
IL279464A (en) Pharmaceutical formulation of odevixibat
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
IL291537A (en) Vaccine preparations containing protein
IL261989A (en) A pharmaceutical preparation of flavociclib and a method for its preparation
HK1255006A1 (zh) 製備治療用蛋白質製劑的方法和由這種方法生產的抗體製劑
LU92648B1 (en) Method and device for optimized freeze-drying of a pharmaceutical product
IL267622A (en) Method for modifying the therapeutic effects of drugs
IL262568A (en) Inactive material based on proteins for active pharmaceutical ingredients
EP3283095A4 (fr) Peptides thérapeutiques pour maladies cérébrovasculaires
EP3491006A4 (fr) Procédé de préparation de protéines ou de peptides
EP3192875A4 (fr) Composition pharmaceutique à libération prolongée destinée au traitement et à la prévention de maladies ophtalmiques
IL273451A (en) Pharmaceutical preparations for administration of peptides
ZA201800470B (en) An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
EP3525772A4 (fr) Formulations destinées à l'administration entérique d'agents thérapeutiques
SG11202104178TA (en) Peptides and pharmaceutical compositions for treating eye diseases
IL268344A (en) A system for use in a pharmaceutical product
EP3375443A4 (fr) Composition pharmaceutique indiquée pour le traitement de maladies liées au système respiratoire
HUE054716T2 (hu) Anti-EGFR-t tartalmazó gyógyászati készítmény
EP3474826A4 (fr) Préparation pharmaceutique pour l'administration de peptides et de protéines
EP3450448A4 (fr) Peptide thérapeutique destiné aux lésions liées à la neurotoxicité excitatrice
KR101809800B9 (ko) 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물
EP3250199A4 (fr) Composition pharmaceutique pour le traitement de maladies gastro-intestinales
EP3562834A4 (fr) Procédé de préparation de peptide